DCR-2 Antibody Targeting CD300f for AML Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) are unsatisfactory, particularly for older patients, and existing antibody therapies have shown limited effectiveness due to toxicity issues with targets like CD33 and other molecules expressed on both leukemia cells and healthy bone marrow cells.
Innovation Solution
Development of a monoclonal antibody, DCR-2, specifically binding to the extracellular domain of CD300f, which is upregulated in AML samples, to provide a targeted therapy with reduced toxicity by enhancing the binding and uptake of therapeutic moieties into AML cells and leukemic stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy or existing antibody therapy is used to treat AML, then leukemia cells may be targeted, but toxicity to healthy bone marrow cells occurs
Solution Approach 1:
The patent applies local quality by selecting a target antigen (CD300f) that is specifically overexpressed on AML cells but not on healthy bone marrow cells. The antibody DCR-2 is designed to bind specifically to this localized target, concentrating the therapeutic effect on leukemia cells while sparing healthy tissue. This resolves the contradiction by making the treatment selectively toxic only to the diseased cells.
Solution Approach 2:
The patent uses an antibody (DCR-2) as an intermediary molecule that bridges the therapeutic agent and the target AML cells. This intermediary provides selective binding to CD300f on leukemia cells, enabling targeted delivery of therapeutic effects while avoiding direct contact with and damage to healthy cells. The intermediary antibody acts as a selective guide that resolves the toxicity problem.
2Reliability
If existing antibody targets like CD33 are used, then AML cells can be targeted, but the antibody binds to both leukemia cells and healthy bone marrow cells
Solution Approach 1:
The patent applies local quality by identifying and targeting CD300f, an antigen with non-uniform distribution - highly expressed on AML cells but absent or minimally expressed on healthy bone marrow cells. The antibody DCR-2 is specifically designed to recognize this localized expression pattern, achieving high target binding on leukemia cells while avoiding off-target binding to healthy cells, thus resolving the contradiction between target binding and off-target effects.
3Reliability
If intensive chemotherapy is administered to younger AML patients, then cure rates improve, but treatment complexity and side effects increase
Solution Approach 1:
The patent replaces the complex mechanical/chemical system of intensive chemotherapy with a more selective biological system - a monoclonal antibody (DCR-2) that naturally seeks out and binds to AML cells through antigen recognition. This substitution simplifies the treatment approach by replacing multi-step chemotherapy protocols with a single targeted antibody therapy that achieves similar or better efficacy with reduced complexity and side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DCR-2 exhibits specific binding to CD300f on AML cells and leukemic stem cells, potentially enhancing therapeutic delivery and inducing antibody-dependent cell-mediated cytotoxicity, offering a more effective treatment option with reduced impact on healthy cells.
Implementation Method 1
DCR-2 exhibits specific binding to CD300f on AML cells and leukemic stem cells
Implementation Method 2
inducing antibody-dependent cell-mediated cytotoxicity
Data Source
AI summary
The present invention relates to an isolated antibody, or antigen binding fragment thereof, which specifically binds to an extracellular domain of CD300f, wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain variable region which comprises: (a) an amino acid sequence that is at least 70% identical to the amino acid sequence represented by SEQ ID NO: 1; and/or (b) a complementarity determining region 1 (CDR1) that comprises the amino acid sequence represented by SEQ ID NO: 2, a complementarity determining region 2 (CDR2) that comprises an amino acid sequence that is represented by SEQ ID NO: 3, and/or a complementarity determining region 3 (CDR3) that comprises an amino acid sequence that is represented by SEQ ID NO: 4, compositions comprising the antibody, antigen binding fragment thereof, and uses for therapy.